ENTRY       D11480                      Drug
NAME        Crizanlizumab (USAN/INN);
            Crizanlizumab-tmca;
            Adakveo (TN)
PRODUCT     ADAKVEO (Novartis Pharmaceuticals Corporation)
FORMULA     C6458H9948N1712O2050S58
EXACT_MASS  146139.0612
MOL_WEIGHT  146230.0981
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKVSGYTFT SYDINWVRQA PGKGLEWMGW IYPGDGSIKY
            NEKFKGRVTM TVDKSTDTAY MELSSLRSED TAVYYCARRG EYGNYEGAMD YWGQGTLVTV
            SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
            SSGLYSLSSV VTVTSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGMEVHNAKT KPREEQFNST
            FRVVSVLTVV HQDWLNGKEY KCAVSNKGLP APIEKTISKT KGQPREPQVY TLPPSREEMT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPGK
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCKASQSVD YDGHSYMNWY QQKPGKAPKL LIYAASNLES
            GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSDENPL TFGGGTKVEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: H22-H96, H136-L218, H149-H205, H224-H'224, H225-H'225, H228-H'228, H231-H'231, H262-H322, H368-H426, H'22-H'96, H'136-L'218, H'149-H'205, H'262-H'322, H'368-H'426, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  TYPE      Peptide
REMARK      ATC code: B06AX01
            Product: D11480<US>
EFFICACY    Anti-anemic, Anti-P-selectin antibody
  DISEASE   Sickle cell disease [DS:H00229]
  TYPE      Monoclonal antibody
COMMENT     Treatment of sickle-cell disease
TARGET      SELP (CD62P) [HSA:6403] [KO:K06496]
  PATHWAY   hsa04514(6403)  Cell adhesion molecules
            hsa04613(6403)  Neutrophil extracellular trap formation
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B06 OTHER HEMATOLOGICAL AGENTS
               B06A OTHER HEMATOLOGICAL AGENTS
                B06AX Other hematological agents
                 B06AX01 Crizanlizumab
                  D11480  Crizanlizumab (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Crizanlizumab
               D11480  Crizanlizumab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: other families
               Selectins
                SELP (CD62P)
                 D11480  Crizanlizumab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11480
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11480
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11480
DBLINKS     CAS: 1690318-25-2
            PubChem: 384585456
///
